Nanomedicine for the treatment of diabetes-associated cardiovascular diseases and fibrosis.
Sign Up to like & getrecommendations! Published in 2021 at "Advanced drug delivery reviews"
DOI: 10.1016/j.addr.2021.01.004
Abstract: Cardiomyopathy and fibrosis are the main causes of heart failure in diabetes patients. For therapeutic purposes, a delivery system is required to enhance antidiabetic drug efficacy and specifically target profibrotic pathways in cardiomyocytes. Nanoparticles (NPs)… read more here.
Keywords: nanomedicine treatment; treatment; diabetes patients; cardiomyopathy fibrosis ... See more keywords